key: cord-0958213-7ex50xag
authors: Delaunois, Annie; Abernathy, Matthew; Anderson, Warren D.; Beattie, Kylie A.; Chaudhary, Khuram W.; Coulot, Julie; Gryshkova, Vitalina; Hebeisen, Simon; Holbrook, Mark; Kramer, James; Kuryshev, Yuri; Leishman, Derek; Lushbough, Isabel; Passini, Elisa; Redfern, Will S.; Rodriguez, Blanca; Rossman, Eric I.; Trovato, Cristian; Wu, Caiyun; Valentin, Jean‐Pierre
title: Applying the CiPA Approach to Evaluate Cardiac Proarrhythmia Risk of some Antimalarials Used Off‐label in the First Wave of COVID‐19
date: 2021-02-23
journal: Clin Transl Sci
DOI: 10.1111/cts.13011
sha: ed14990ba3eabd4f42ac2621c1bab633d1e34415
doc_id: 958213
cord_uid: 7ex50xag

We applied a set of in silico and in vitro assays, compliant with the CiPA (Comprehensive In Vitro Proarrhythmia Assay) paradigm, to assess the risk of chloroquine or hydroxychloroquine‐mediated QT prolongation and Torsades de Pointes (TdP), alone and combined with erythromycin and azithromycin, drugs repurposed during the first wave of COVID‐19. Each drug or drug combination was tested in patch clamp assays on 7 cardiac ion channels, in in silico models of human ventricular electrophysiology (Virtual Assay(®)) using control (healthy) or high‐risk cell populations, and in human induced pluripotent stem cell (hiPSC)‐derived cardiomyocytes. In each assay, concentration‐response curves encompassing and exceeding therapeutic free plasma levels were generated. Both chloroquine and hydroxychloroquine showed blocking activity against some potassium, sodium and calcium currents. Chloroquine and hydroxychloroquine inhibited I(Kr) (IC(50): 1µM and 3‐7µM, respectively) and I(K1) currents (IC(50): 5 and 44µM, respectively). When combining hydroxychloroquine with azithromycin, no synergistic effects were observed. The two macrolides had no or very weak effects on the ion currents (IC(50)>300‐1000µM). Using Virtual Assay(®), both antimalarials affected several TdP indicators, chloroquine being more potent than hydroxychloroquine. Effects were more pronounced in the high‐risk cell population. In hiPSC‐derived cardiomyocytes, all drugs showed early‐after‐depolarizations, except azithromycin. Combining chloroquine or hydroxychloroquine with a macrolide did not aggravate their effects. In conclusion, our integrated nonclinical CiPA dataset confirmed that, at therapeutic plasma concentrations relevant for malaria or off‐label use in COVID‐19, chloroquine and hydroxychloroquine use is associated with a proarrhythmia risk, which is higher in populations carrying predisposing factors but not worsened with macrolide combination.

The concept of the Comprehensive in vitro Proarrhythmia Assay (CiPA) paradigm was proposed jointly by the US Food and Drug Administration (FDA), the Health and Environmental Sciences Institute (HESI) and the Cardiac Safety Research Consortium (CSRC) in 2013 to improve on prediction of risk of Torsade de Pointes (TdP) for small molecule pharmaceuticals 1, 2, 3, 4 . It comprises both nonclinical and clinical components. The three nonclinical elements of CiPA are optimization and standardization of automated cardiac ion channel assays, in silico modelling of the effects on action potential shape from the known interactions of the compound across key cardiac ion channels, and effects of the compound on action potential and contractility biomarkers in human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes. Although the CiPA paradigm is still being refined and validated, we took the opportunity to 'road-test' this approach with some repurposed drugs that have recently been under intense clinical, media and public scrutiny.

Chloroquine (CLQ) and hydroxychloroquine (OH-CLQ) are long-established medicines used for prophylaxis and treatment of uncomplicated malaria or some autoimmune diseases. Their use has been associated with cardiovascular side effects, in particular QT interval prolongation and TdP 5 .

CLQ and OH-CLQ were developed and marketed long before the introduction of the ICH S7B 6 and E14 7 guidelines, which provide recommendations for the nonclinical and clinical assessment of the potential of a new drug to delay ventricular repolarization and prolong QT interval.

Consequently, the availability of high quality, nonclinical and clinical cardiovascular data, meeting current and emerging scientific best practices and regulatory framework 8, 9 , is relatively limited. A few former publications reported that CLQ inhibits I Kr current with an IC 50 value of 2.5µM 10 and prolongs QTc interval in ex vivo and in vivo rabbit models 11 , as well as in healthy subjects 12 .

When the new coronavirus disease COVID-19 appeared in December 2019, early in vitro studies reported antiviral activity of CLQ and OH-CLQ against the SARS-CoV-2 13, 14 . These findings triggered the initiation of several clinical trials and their use in the hospital setting to treat severe COVID-19 cases, usually combined with a macrolide antibiotic such as azithromycin (AZI) or

This article is protected by copyright. All rights reserved erythromycin (ERT). Although preliminary results showed reduced viral carriage in a small sample of COVID-19 patients 15 , these promising findings were not confirmed subsequently by larger studies such as the RECOVERY trial 16 . Moreover, an increased risk of cardiovascular mortality and heart failure was reported when OH-CLQ was co-administered with AZI 17 . Another study conducted in 73 patients with SARS-CoV-2 infection found an average QT prolongation of 23ms after 48 hours of OH-CLQ/AZI combined therapy 18 .

In the context of COVID-19, the TdP liability of these medications used alone or in combination could aggravate the clinical state of the patients and explain the increased risk of mortality.

Consequently, the objective of the current work was to assess the proarrhythmic profile of CLQ, OH-CLQ, AZI and ERT, alone or in combination, using the full battery of in silico and in vitro assays proposed by the CiPA paradigm which included cardiac ion current patch clamp assays, in silico drug simulations on virtual human ventricular myocytes, and hiPSC-derived cardiomyocytes.

Chinese hamster ovary cells stably transfected with the human cardiac isoforms of hERG, Na V 1.5, Ca V 1.2 (coexpressed with β2/α2δ1), K V 4.3 (coexpressed with KChiP2.2), K V 7.1/minK, or K ir 2.1 were cultured in HAM/F12, while HEK 293 cells stably expressing HCN4 were cultured in a 1:1 mix of HAM/F12 and DMEM/F12 medium. All media were supplemented with 10% FBS and 1%

Penicillin/Streptomycin at 37°C, 5% CO 2 and saturated humidity.

For Dataset #1, shortly before experimentation, the cells were harvested with Detachin TM 2-3 days after plating at a confluence of 70% and resuspended in PBS. All experiments were performed with automated patch-clamp using QPatch (16X and HTX, Sophion Bioscience) at room temperature.

For Dataset #2, before testing, cells in culture dishes were washed twice with Hank's Balanced Salt Solution (HBSS) and treated with Accutase TM for approximately 20 minutes. Immediately before use in SP384PE, the cells were washed in HBSS to remove the Accutase TM and resuspended in HB-PS. The drug formulations were loaded in a 384-well polypropylene compound

This article is protected by copyright. All rights reserved plate using an automated liquid handling system (Integra Assist Plus, Integra), and placed in the plate well of SyncroPatch 384PE (SP384PE; Nanion Technologies, Livingston, NJ) immediately before application to the cells. hERG and Na V 1.5 experiments were run at 37°C, while Ca V 1.2, K V 7.1/minK and HCN4 were run at room temperature.

The composition of extracellular and intracellular solutions, the voltage protocols, as well as the positive controls used for each current assay are described in the Supplementary Methods. hERG, Na V 1.5, Ca V 1.2, and K V 4.3-mediated currents were recorded and analysed as recommended by U.S. Food and Drug Administration (FDA) 19 where X is the drug concentration, IC 50 is the concentration producing half-maximal inhibition, and H is the Hill coefficient.

For hERG experiments testing potential interaction between two drugs, the first drug was perfused until steady state current amplitude was reached and then increasing concentrations of the second drug were added, whilst maintaining the fixed concentration of the first drug. Drug combinations blocking 50% of I Kr current were analysed in an isobologram 20 .

Human in silico drug trials were performed using the software Virtual Assay ® (v. 3 

population (~400 cells) and a high-risk population (~100 cells) were constructed, for a total of 6 in silico populations of virtual human ventricular cells. All cell populations implement biological variability by randomly varying the main ionic current conductances of the AP models, and are able to capture different drug-induced phenotypes, i.e. repolarisation abnormalities (RA) and depolarisation abnormalities (DA) 23 . However, the high-risk population has been specifically designed with a low repolarisation reserve, to maximise the risk to develop RA 24 .

Simulations were performed for CLQ, OH-CLQ, AZI, and ERT at multiple concentrations (from 0.5 to 1000µM), using the two IC 50 and Hill coefficient (H) datasets listed in Table 1 as input of a simple pore-block model 29 . Four drug combinations were also simulated (CLQ+AZI, CLQ+ERT, OH-CLQ+AZI, OH-CLQ+ERT), by considering equal concentrations of each drug (from 0.5 to 1000µM) and assuming a cumulative effect of their ion channel blocks.

Thirteen AP and calcium transient (CT) biomarkers were computed for the cells not displaying RA nor DA: AP duration at 40%, 50%, and 90% of repolarisation (APD 40 , APD 50 , and APD 90 ); AP triangulation, defined as the difference between APD 90 and APD 40 (Tri 90-40 ); maximum upstroke velocity (dV/dt MAX ); peak voltage (V peak ); resting membrane potential (RMP); CT duration at 50% and 90% of repolarisation (CTD 50 and CTD 90 ); CT peak (CT peak ); CT amplitude (CT Amp ); diastolic intracellular Ca 2+ concentration (Ca i,dias ); electromechanical window (EMw), defined as the difference between APD 90 and CTD 90 24 . For ORd-CiPA, we also computed the net charge carried by ionic currents (qNet), as described in 27 . However, it is worth noting that drugs effects on the hERG channel were represented with a simple pore-block model, since the experimental data needed to parametrize the dynamic hERG model were not available. AP traces displaying a positive derivative after 150ms were classified as RA, while AP traces with a V peak < 0mV were classified as DA. A more detailed description of the in silico drug trial methods is included in the Supplementary Methods.

Experiments on hiPSC cardiomyocytes were adapted from a protocol previously described 30 amplitude as well ECR data, sodium spike and field potential duration (FPD) were recorded and analysed by RTCA CardioECR software at baseline, 30min, 1h, 6h, 12h and 24h post-treatment.

Composite plots (QT-ograms) were constructed using free concentrations of each drug and % change in QT-related biomarkers generated in the different assays, i.e. I Kr current from both patch clamp datasets and APD 90 as well as EMw simulations in control population of virtual human cardiomyocytes (from Table 2 ). For CLQ, % QTc increase in man were extracted from the clinical study GSK protocol TAF106491 (clinicaltrials.gov identifier NCT00871156) 31 and were calculated assuming a baseline QTc of 400ms. Free plasma concentration (FPC) of each drug was estimated based on pharmacokinetic data retrieved from PharmaPendium ® database 32 or literature references 33, 34, 35, and was considered to be 0.4µM for a 500mg dose of CLQ, 0.5µM for a 400mg dose of OH-CLQ and 0.5µM for a 500mg dose of AZI and ERT. 

Simulation results are overall consistent across the 6 in silico cell populations and the 2 IC 50 /H datasets, both for drug-induced changes in AP and CT biomarkers, and occurrence of RA and DA. Table 2 show a selection of the results obtained with the ToR-ORd model and the Dataset #1 (from Table 1 ). The full set of results obtained with the three computational models, the two datasets, and the two population types (control and high-risk) is given in Table S2 and Figure S1 . Table 2 , showing the minimum tested concentration at which drug-induced changes for a selection of in silico AP and CT biomarkers were >20% compared to control conditions. with no relevant differences between the control and high-risk populations. Results for drug combinations were similar to the ones obtained for CLQ and OH-CLQ alone. As representative example, AP and CT traces for 5μM CLQ are shown in Figure 3B and Figure 3C . The CiPA qNet biomarker showed a notable reduction for CLQ and OH-CLQ, while remaining almost unchanged for AZI and ERT (Figure 4 ). Based on the thresholds suggested in 36 , CLQ could be classified as high risk, OH-CLQ as medium risk, and AZI and ERT as low risk drugs. 

This article is protected by copyright. All rights reserved was not higher than 20% as compared to DMSO. Combining CLQ with 10µM ERT showed similar effects on cardiomyocytes as with CLQ applied alone, but with EADs observed even at lower concentrations than with CLQ alone. When CLQ was combined with AZI, EADs were not observed any longer and instead of a negative, a positive chronotropy was observed. Similar changes were observed when OH-CLQ was combined with AZI or ERT.

The CLQ 'QT-ogram' ( Figure 5A ) illustrates that biologically relevant changes (>10-20%) in QTrelated biomarkers can occur below or close to the FPC (<3-fold). All nonclinical data are consistent together and also fit with the QT prolongation observed in man in the same concentration range. Similar profile is noted for OH-CLQ ( Figure 5B ), with slightly larger safety ratios based on in silico simulations. In contrast, AZI and ERT QT-ograms show more favorable cardiac safety profile, the first relevant effects appearing around 30-fold the FPC for ERT ( Figure   5D ) and above 300-fold the FPC for AZI ( Figure 5C ).

The present work 'road-tested' the new CiPA paradigm 1, 2, 3, 4 , aiming at assessing the proarrhythmic risk of drugs using human-based models, with CLQ and OH-CLQ, two long- Patch clamp assays conducted on mammalian cells transfected with genes encoding for human ion channels confirmed that both CLQ and OH-CLQ are I Kr current inhibitors. Our IC 50 values in the micromolar range are in agreement with the previously published value for CLQ (2.5µM) 10 . Our

This article is protected by copyright. All rights reserved data also confirms that CLQ can inhibit I K1 current regulating the late phase of ventricular repolarization, with an IC 50 of 4.98µM fitting with the value previously reported (8.7µM) 38 .

Blockade of I K1 current has also been associated with long QT 39 

This article is protected by copyright. All rights reserved two patch clamp datasets, both antimalarial drugs consistently increase action potential durations, an in vitro surrogate biomarker of QT, and affect several TdP indicators, such as EMw, qNet, and trigger repolarization abnormalities. This is particularly true for high-risk populations. No major effects were observed for AZI nor ERT. Using qNet, we were able to classify the four drugs in terms of their TdP risk. However, it is worth noting that the qNet biomarker is highly sensitive to variation in the model parameters (distribution in the population compared to single model results). Therefore, thresholds based on percent changes rather than absolute values might be more appropriate for risk predictions. In addition, the qNet biomarker was also observed to be highly 

This article is protected by copyright. All rights reserved human iPSC-derived cardiomyocytes, in which the combination of ERT or AZI with CLQ or OH-CLQ did not seem to aggravate the proarrhythmic indicators at clinically relevant concentrations.

It is important to consider that our integrated risk assessment is based on peak plasma levels obtained after single administration (i.e. C max ), and that the drugs could potentially accumulate into cardiac tissue after repeat administration of high doses of CLQ or OH-CLQ over a few successive days, as applied in the treatment of malaria or in COVID-19 patients. Moreover, in addition to the well-known increased cardiovascular risk of some patient populations such as elderly people, diabetics, or subjects with preexisting heart disease, it has now been clearly demonstrated that COVID-19 itself triggers, even in young subjects, pathological situations such as electrolyte imbalance 45 and cardiovascular disorders such as myocardial injury, arrhythmias, acute coronary syndrome 46 .

Although we acknowledge the limitations of our work, since no in vivo QT data were generated as 

What is the current knowledge on the topic?

The antimalarials CLQ or OH-CLQ used off-label in combination with a macrolide antibiotic (ERT or AZI) during the first wave of COVID-19 have been long associated with cardiovascular side effects, namely QT prolongation. There is a paucity of nonclinical data, meeting the new CiPA paradigm, to properly assess the proarrhythmic risk of these drugs, used alone as antimalarials or combined with a macrolide, such as in some COVID-19 clinical trials.

-What is the propensity of CLQ and OH-CLQ to affect cardiac ion currents and to delay ventricular repolarization using the set of in vitro and in silico assays proposed by the CiPA approach?

-What is the associated safety margin compared to therapeutic plasma levels?

-Does the combination with AZI or ERT aggravate this risk?

What does this study add to our knowledge? 

This article is protected by copyright. All rights reserved 

Comprehensive in vitro Proarrhythmia Assay, a novel in vitro/in silico paradigm to detect ventricular proarrhythmic liability: a visionary 21st century initiative

Evolution of strategies to improve preclinical cardiac safety testing

A new perspective in the field of cardiac safety testing through the Comprehensive In Vitro Proarrhythmia Assay paradigm

Mechanistic model-informed proarrhythmic risk assessment of drugs: review of the "CiPA" initiative and design of a prospective clinical validation study

Cardiotoxicity of antimalarial drugs. The Lancet Infectious Diseases

The nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals

The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for nonantiarrhythmic drugs

ICH E14/S7B Implementation Working Group: Clinical and nonclinical evaluation of QT/QTc interval prolongation and proarrhythmic potential: Questions and Answers

Inhibition of hERG K + currents by antimalarial drugs in stably transfected HEK293 cells

Assessment of proarrhythmic activity of chloroquine in in vivo and ex vivo rabbit models

The pharmacokinetics and electrocardiographic effects of chloroquine in healthy subjects

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial

Effect of hydroxychloroquine in hospitalized patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial

Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study

QT interval prolongation under hydroxychloroquine/ azithromycin association for inpatients with SARS-CoV-2 lower respiratory tract infection

Recommended voltage protocols to study drug-cardiac ion channel interactions using recombinant cell lines

Experimentally calibrated population of models predicts and explains intersubject variability in cardiac cellular electrophysiology

Variability in cardiac electrophysiology: Using experimentally-calibrated populations of models to move beyond the single virtual physiological human paradigm

Human in silico drug trials demonstrate higher accuracy than animal models in predicting clinical pro-arrhythmic cardiotoxicity

Drug-induced Shortening of the Electromechanical Window is an Effective Biomarker for in Silico Prediction of Clinical Risk of Arrhythmias

Blinded in silico drug trial reveals the minimum set of ion channels for Torsades de Pointes risk assessment

Development, calibration, and validation of a novel human ventricular myocyte model in health, disease, and drug block

Optimization of an in silico cardiac cell model for proarrhythmia risk assessment

Accepted Article This article is protected by copyright. All rights reserved

Simulation of the undiseased human cardiac ventricular action potential: Model formulation and experimental validation

Multiscale modelling of drug-induced effects on cardiac electrophysiological activity

Use of human induced pluripotent stem cellderived cardiomyocytes (hiPSC-CMs) to monitor compound effects on cardiac myocyte signaling pathways

TAF 106491 study

Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax

Blood, tissue, and intracellular concentrations of erythromycin and its metabolite anhydroerythromycin during and after therapy

Blood, tissue, and intracellular concentrations of azithromycin during and after end of therapy

Assessment of an in silico mechanistic model for proarrhythmia risk prediction under the CiPA initiative

Predicting cardiac safety using human induced pluripotent stem cell-derived cardiomyocytes combined with multi-electrode array (MEA) technology: A conference report

The molecular basis of chloroquine block of the inward rectifier Kir2.1 channel

Drug-induced inhibition and trafficking disruption of ion channels: pathogenesis of QT abnormalities and drug-induced fatal arrhythmias

Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-cov-2) infection: a randomized clinical trial

Effects are expressed as absolute % change from control conditions (% inhibition for hERG, % increase in APD 90 or % decrease in EMw for virtual cardiomyocytes). For CLQ, % QTc increase in man (crosses) are extracted from the clinical study GSK protocol TAF106491 (clinicaltrials.gov identifier NCT00871156) and were estimated assuming a baseline QTc of 400ms

This article is protected by copyright. All rights reserved